Pamela Morris to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Pamela Morris has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.763
-
Gemfibrozil in Combination with Statins-Is It Really Contraindicated? Curr Atheroscler Rep. 2016 Apr; 18(4):18.
Score: 0.452
-
What the guidelines do not say: statin non-benefit groups. Curr Atheroscler Rep. 2015 Jan; 17(1):468.
Score: 0.415
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
Score: 0.176
-
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
Score: 0.131
-
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
Score: 0.130
-
Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol. 2017 Sep 05; 70(10):1290-1301.
Score: 0.125
-
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 11 22; 134(21):e468-e495.
Score: 0.117
-
Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. J Clin Lipidol. 2016 May-Jun; 10(3):458-61.
Score: 0.113
-
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
Score: 0.041
-
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
Score: 0.036
-
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
Score: 0.028